Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Krieger

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of the American Medical Directors Association|March 25, 2014
Motoneuron loss is associated with sarcopeniaMichael Drey, Benjamin Krieger, Cornel C Sieber, et al.
Cytometry. Part B, Clinical Cytometry|November 14, 2015
Vascular Health Profile predicts cardiovascular outcomes in patients with diabetesWade T Rogers, Lifeng Zhang, Scott Welden, et al.
Respirology (Carlton, Vic.)|July 17, 2024
COPD is associated with increased cardiovascular disease risk independent of phenotypeKolton Cobb, Jonathan Kenyon, Juan Lu, et al.
Oncotarget|June 2, 2018
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing diseaseStefanie Zschäbitz, Florian A Distler, Benjamin Krieger, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of the American Medical Directors Association|March 25, 2014
Motoneuron loss is associated with sarcopeniaMichael Drey, Benjamin Krieger, Cornel C Sieber, et al.
Cytometry. Part B, Clinical Cytometry|November 14, 2015
Vascular Health Profile predicts cardiovascular outcomes in patients with diabetesWade T Rogers, Lifeng Zhang, Scott Welden, et al.
Respirology (Carlton, Vic.)|July 17, 2024
COPD is associated with increased cardiovascular disease risk independent of phenotypeKolton Cobb, Jonathan Kenyon, Juan Lu, et al.
Oncotarget|June 2, 2018
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing diseaseStefanie Zschäbitz, Florian A Distler, Benjamin Krieger, et al.
Pageof 1